Targeting MRG15 for the treatment of nonalcoholic steatohepatitis

Non-alcoholic fatty liver disease represents the most common liver disease worldwide and the prevailing cause of liver-related morbidity and mortality. It encompasses a broad clinical spectrum ranging from nonalcoholic fatty liver to nonalcoholic steatohepatitis (NASH), advanced fibrosis, cirrhosis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yao, Dalamaga, Maria, Liu, Junli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719851/
https://www.ncbi.nlm.nih.gov/pubmed/36478775
http://dx.doi.org/10.1016/j.metop.2022.100217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719851/
https://www.ncbi.nlm.nih.gov/pubmed/36478775
http://dx.doi.org/10.1016/j.metop.2022.100217

Ejemplares similares